Aliskiren
規格
173334-57-1CAS番号
605-672-4EC番号
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamideIUPAC名
C30H53N3O6化学式
551.8 g/mol分子量
Aliskiren; 173334-57-1; SPP100; SPP 100; aliskirene; Aliskireno; SPP-100; CGP 60536; 502FWN4Q32; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; CHEBI:601027; DTXSID40891494; CGP-060536B; CGP-60536; aliskirenum; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-((4-methoxy-3-(3-methoxypropoxy)phenyl)methyl)-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamide; RefChem:56248; C09XA02; CGP060536B; DTXCID401030595; CGP60536; Aliskiren(CGP 60536); MFCD09839018; CHEMBL1639; CGP60536B; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; Aliskiren [INN]; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C30H53N3O6; NCGC00186464-01; CGP 60536;CGP60536B;SPP 100; Aliskiren [USAN:INN:BAN]; UNII-502FWN4Q32; Aliskiren?; HSDB 7843; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; Rasilez (TN); Aliskiren (Standard); Aliskiren-hemifumarate; ALISKIREN [MI]; Aliskiren (USAN/INN); ALISKIREN [HSDB]; ALISKIREN [USAN]; ALISKIREN [VANDF]; ALISKIREN [WHO-DD]; ALISKIREN [EMA EPAR]; SCHEMBL455490; GTPL4812; orb1704862; SCHEMBL29521564; BDBM17950; UXOWGYHJODZGMF-QORCZRPOSA-N; GLXC-05705; ALBB-027274; MSK11172; EBC-27307; HY-12176R; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; NCGC00186464-02; NCGC00186464-13; AS-80517; FA134549; HY-12176; SBI-0206888.P001; NS00007787; D03208; EN300-708809; T22233; AB01274865-01; AB01274865_02; AB01274865_03; F793779; Q414904; BRD-K30020243-051-01-7; BRD-K30020243-051-02-5; BRD-K30020243-051-03-3; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; 5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide fumar ate; Benzeneoctanamide, |A-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-|A-hydroxy-4-methoxy-3-(3-methoxypropoxy)-|A,|AE-bis(1-methylethyl)-, (|AS,|AS,|AS,|AES)-; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-me thylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C41別名
Aliskirenを含む製品
RASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAliskirenAliskirenAliskiren